1.Research progress on the function of angiotensin Ⅱ receptors in tumor
Yanchun ZHANG ; Jinpei ZHOU ; Xiaoming WU
Chinese Pharmacological Bulletin 1986;0(04):-
AngiotensinⅡ is a biologically activated peptide of the rennin-angiotensin system(RAS).Beside constracting vascular and regulating blood pressure,AngⅡplays an important role in the development of tumor,inflammation and angiogenesis.The expression and major intracellular signaling pathways of AngⅡ and AngⅡ receptors in tumor are reviewed.
2.Advances in indoleamine 2, 3-dioxygenase 1 inhibitors
Yulan CHENG ; Jinxia MEN ; Jinpei ZHOU ; Huibin ZHANG
Journal of China Pharmaceutical University 2017;48(3):361-370
Indoleamine 2,3-dioxygenase 1 (IDO1) is the rate-limiting enzyme which catalyses the metabolism of L-tryptophan(L-Trp) in the kynurenine pathway.It is overexpressed in many tumor cells and antigen presenting cells.This enzyme inhibits local immune response and supports tumor cells to evade immune surveillance by depleting L-Trp and producing kynurenine metabolites,thus,it is an important target for cancer immunotherapy.There are several IDO1 inhibitors with different scarfold under investigation,three of which have already entered clinical stage.The role of IDO1 in tumor immune tolerance and the research progress on IDO1 inhibitors in recent years are summarized in this paper.
3.Advances in antidiabetic small molecule ABHD6 inhibitors
Lianghui SI ; Hui MA ; Jinpei ZHOU ; Huibin ZHANG
Journal of China Pharmaceutical University 2017;48(2):125-134
Type 2 diabetes,a glucose and lipid metabolism disorder accompanied by chronic multiple organ damage,has become a huge threat to human health,α/β hydrolase domain-6 (ABHD6) regulates the insulin release negatively by hydrolyzing monoacylglycerol.Small molecule ABHD6 inhibitors have been proven to lower bloodglucose and regulates energy homeostasis,which is a potential candidate for the treatment of type 2 diabetes.This paper introduced the ABHD6 signaling pathway and its mechanism,then reviewed the progress of small molecule ABHD6 inhibitors with different structures in recent years,and analyzed the structure activity relationship.
4.Synthesis of Tacrine
Huibin ZHANG ; Jinpei ZHOU ; Wenlong HUANG
Chinese Journal of Modern Applied Pharmacy 2001;18(1):44-45
OBJECTIVE:To synthesize Tacrine,a new drug for the treatment of Alzheimer′s disease.METHOD:With the 2-aminobenzoic acid as the starting material,Tacring was synthesized via condensation-cyclization,chlorization and amination.RESULTS:Each step was modified and improved.The overall yields was 40.7%.The melting point and IR、1HNMR of the product prepared were identical as that of the reportedone.CONCLUSION:The process can be easily controled and is suitable for a scale production.
5.Influence of stigma on QOL of patients with mental disorders
Ying ZHOU ; Shengmao PAN ; Chunyang ZHAO ; Jiankui LIN ; Yajie LI ; Jinpei ZHANG ; Lianqi LIU
Chongqing Medicine 2015;(10):1349-1351
Objective To investigate the influence of stigma on QOL of patients with mental disorders.Methods By using Link stigma series scale and schizophrenic quality of life scale,we assessed and analyzed 406 psychiatric patients′stigma and QOL, as well as the correlation and influence between them.Results The score of perceived devaluation-discrimination dimension of the stigma scale had positive correlation with total score of QOL,score of psycho-social dimension and score of motivation and energy dimension (P <0.05).The scores of challenge dimension and separation dimension in the stigma scale had positive correlation with motivation and energy dimension of the QOL scale (P <0.05).Regression analysis showed that stigma did not have influence on QOL of patients with mental disorders.Conclusion Stigma in psychiatric patients has no significant influence on QOL,but correla-tion relationship exists between them.The higher score of perceived devaluation-discrimination dimension,challenge dimension and separation dimension of stigma scale,the poor QOL the patient would have.
6.Design, synthesis and antiplatelet evaluation of tetramethylpyrazine/chalcone hybrids
Yang GAO ; Wei YIN ; Jingchao LIU ; Fenghua KANG ; Yanlin JIAN ; Jinpei ZHOU ; Zhangjian HUANG ; Yihua ZHANG
Journal of China Pharmaceutical University 2017;48(1):23-30
In order to search for new antiplatelet agents with higher potency, a series of tetramethylpyrazine ( TMP) /chalcone hybrids ( 2-26) were synthesized and evaluated based on the principle of bioisostere and hybrid-ization. They exerted inhibitory activity against adenosine diphosphate ( ADP )-induced and arachidonic acid ( AA)-induced platelet aggregation to varied extent. Among them, compound 8 was the most potent with IC50 of 0. 14 mmol/L on ADP-induced platelet aggregation ( 9. 1 folds of TMP and 10. 5 folds of chalcone ) and 0. 09 mmol/L on AA-induced platelet aggregation ( 8. 8 folds of TMP and 10. 0 folds of chalcone) , which was superior to clinically used anti-platelet drug aspirin ( ASP, IC50 =0. 15 mmol/L) .
7.Inhibitory effects of Yinchenhao Decoction on fatty deposition and TNF-? secretion in HepG2 cells induced by free fatty acid
Shaodong CHEN ; Haihong ZHOU ; Xuemei LI ; Jinpei LIN ; Ying FAN ; Weijia XU
China Journal of Traditional Chinese Medicine and Pharmacy 2006;0(09):-
Objective:To study the effects of effective herbs in Yinchenhao Decoction(YD)on fatty deposition and TNF-?secretion of hepatic lipo-toxicity model in vitro.Methods:TG and TNF-?as the inspection target,apply the steatosis with TNF-?secretion lipo-toxicity model in vitro of HepG2 induced by long-chain FFA and uniform design U7(76)form for YD,which had 3 herbs,to compound 6 kinds of different prescriptions,in order to look for the effective herbs or optimized group in YD.Results:The Chinese medicine Yinchen and its optimized group-Yinchen and Zhizi combination can remarkably reduce the TG and TNF-?content.Conclusion:The Chinese medicine Yinchen and its optimized group-Yinchen and Zhizi combination were effective herbs in YD for inhibiting fatty deposition and TNF-?secretion of hepatic lipo-toxicity model in vitro.
8.Recent research progress in small molecule AMPK direct activators
Qiangqiang WEI ; Wenhu DUAN ; Jinpei ZHOU ; Huibin ZHANG
Journal of China Pharmaceutical University 2015;46(4):406-415
Type 2 diabetes, an epidemic disorder characterized by high blood glucose level associated with microvascular complications, is one of the main causes of human suffer across the globe, with no effective medicine up to now. AMP-activated protein kinase(AMPK), a highly conserved serine/threonine protein kinase, is a key sensor and regulator of intracellular and whole-body energy metabolism. Small molecule AMPK direct activators have been proven to lower blood-glucose, which is a promising candidate for the treatment of type 2 diabetes. The progress on the research of small molecule AMPK direct activators in recent years is summarized in this paper.
9.Research progress of mitogen-activated protein kinase interacting kinases inhibitors in tumor immunotherapy
Hong BU ; Jinpei ZHOU ; Huibin ZHANG
Journal of China Pharmaceutical University 2021;52(4):410-421
With the rise of tumor immunotherapy, small molecule modulators targeting the immune system have become a research hotspot. As well-developed and mature targets, immunity protein kinases have attracted more and more attention. Mitogen-activated protein kinase (MAPK)-interacting kinases (MNKs) are located at the meeting-point of ERK and p38 MAPK signaling pathways, which can phosphorylate eukaryotic translation initiation factor 4E (eIF4E) at the conserved serine 209 exclusively and modulate the translation of mRNA. Herein we review the structural characteristics, mechanism, signaling transduction pathways and close relationship with tumors of MNKs.Meanwhile, the development process and clinical research progress of the MNKs inhibitors reported by different research institutions are introduced in detail.
10.Advances in small molecule inhibitors of PD-1/PD-L1 immune checkpoint pathway
Jiping TIAN ; Jian ZHANG ; Jinpei ZHOU ; Huibin ZHANG
Journal of China Pharmaceutical University 2019;50(1):1-10
Studies have found that a variety of tumors continue to activate PD-1(programmed cell death protein 1, PD-1)/PD-L1(programmed cell death-ligand 1)signaling pathway by up-regulating PD-L1 expression in tumor cells and microenvironment. The dysfunction of T cells leads to the occurrence of tumor immune escape. Several PD-1/PD-L1 monoclonal antibodies have been marketed to achieve significant clinical efficacy. However, because of the high production cost, the harsh conditions for storage and transportation, and the potential immunogenicity of monoclonal antibody, the seeking for PD-1/PD-L1 small molecule inhibitors has become a hot spot in the development of new drugs. In this paper, the biological mechanisms of PD-1/PD-L1 was introduced in detail. Based on the structural classification, the research progress of PD-1/PD-L1 small molecule inhibitors was reviewed, with a prospect of the development of small molecule inhibitors.